Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?


Journal Article

The changing epidemiology of invasive candidiasis, along with concerns for the emergence of drug resistance, necessitates the identification of patients at increased risk of non-albicans Candida (NAC) to optimize selection of antifungal therapy. The major findings of a study regarding the demographic characteristics, costs, and outcomes of nonneutropenic patients with candidemia due to NAC are discussed. Given available treatment options, such risk assessment is most relevant to initial empiric therapy in stable patients without neutropenia who might be candidates for initial therapy with an azole (eg, fluconazole). The study's investigators reinforce the need for timely antifungal therapy for patients with candidemia.

Full Text

Duke Authors

Cited Authors

  • Drew, RH

Published Date

  • April 2007

Published In

Volume / Issue

  • 41 / 4

Start / End Page

  • 690 - 692

PubMed ID

  • 17389669

Pubmed Central ID

  • 17389669

Electronic International Standard Serial Number (EISSN)

  • 1542-6270

Digital Object Identifier (DOI)

  • 10.1345/aph.1K051


  • eng

Conference Location

  • United States